Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #66 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Alembic Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4).
As stated in Alembic Pharmaceuticals Ltd's Q2 FY27 investor presentation · published 4 Nov 2026. Reported figures, not investment advice.
Based on Alembic Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4). EBITDA for Q2 FY27: ₹5.78 billion, up 78% YoY.
From Alembic Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 4 Nov 2026.
How did Alembic Pharmaceuticals' revenue grow in the September 2026 quarter?
- Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4)
- US Formulation Revenue Q2 FY27: ₹10.03 billion, 77% growth YoY (Page 9, Page 4)
- India Branded Business Revenue Q2 FY27: ₹7.25 billion, 14% growth YoY (Page 6, Page 4)
- Ex-US Formulation Revenue Q2 FY27: ₹4.40 billion, 12% growth YoY (Page 10, Page 4)
2 more points from Alembic Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
What happened to Alembic Pharmaceuticals' margins in Q2 FY27?
See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Alembic Pharmaceuticals planning?
- Capex trend over FY23 to FY26 shows continuous increase: ₹4.12 bn (FY23), ₹3.45 bn (FY24), ₹5.75 bn (FY25), ₹4.32 bn (FY26) (Page 21).
- Indore facility commissioned and acquisition of Utility Therapeutics Limited completed in 2025 (Page 18).
- ESG-related infrastructure includes development of 112 recharge wells + check dams for water neutrality by 2027, achieved 100% water positivity (Page 20).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Alembic Pharmaceuticals raising money or cutting debt?
See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Alembic Pharmaceuticals' order book?
See what Alembic Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹2.1K Cr, net profit ₹172 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Biocon Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹4,389 Cr, up 2% YoY . Key investor presentation takeaways from Biocon Ltd's Q2 FY27 investor presentation — and how it ranks a
- Marksans Pharma Ltd (Q2 FY27)
Q2FY27 Total Income: ₹958.3 crore (29.2% YoY growth) . Key investor presentation takeaways from Marksans Pharma Ltd's Q2 FY27 investor presentation — and how it
- Zydus Lifesciences (Q2 FY27)
79,096 mn, up 29.2% YoY (Page 14) . Key investor presentation takeaways from Zydus Lifesciences Ltd's Q2 FY27 investor presentation — and how it ranks against s
- Lupin (Q2 FY27)
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13) . Key investor presentation takeaways from Lupin Ltd's Q2 FY27 investor presentation — and how it ran
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q2 FY27 results?
Total Revenue for Q2 FY27: ₹26.03 billion, up 36% YoY (Page 12, Page 4). EBITDA for Q2 FY27: ₹5.78 billion, up 78% YoY.
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 21.1 with a market cap of ₹15,780 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
Capex trend over FY23 to FY26 shows continuous increase: ₹4.12 bn (FY23), ₹3.45 bn (FY24), ₹5.75 bn (FY25), ₹4.32 bn (FY26) (Page 21).
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.